Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.

[1]  G. Pond,et al.  Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. , 2013, European urology.

[2]  E. Plimack,et al.  Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Schwartz,et al.  Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. , 2012, The Lancet. Oncology.

[4]  P. Kantoff,et al.  Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Fimmers,et al.  Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  G. Sonpavde,et al.  Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. , 2010, The Lancet. Oncology.

[7]  A. Eisen,et al.  A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma. , 2010 .

[8]  G. Sonpavde,et al.  Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Culine,et al.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Tangen,et al.  Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium , 2010, BJU international.

[11]  S. Culine,et al.  Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  David C. Smith,et al.  Vinflunine in platinum‐pretreated patients with locally advanced or metastatic urothelial carcinoma , 2009, Cancer.

[13]  R. Autorino,et al.  Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients , 2009, Cancer.

[14]  C. Ryan,et al.  Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy. , 2008, Clinical genitourinary cancer.

[15]  S. Culine,et al.  A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen , 2006, British Journal of Cancer.

[16]  L. Collette,et al.  Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. , 2006, European journal of cancer.

[17]  Sergio Ricci,et al.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Sternberg,et al.  Chemotherapy with an every‐2‐week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin‐based therapy , 2001, Cancer.

[19]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[20]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[21]  I. Tannock,et al.  Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.